Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 324, Issue 2, pp 116–124 | Cite as

Evidence for common pharmacological properties of [3H]5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves

  • G. Engel
  • M. Göthert
  • E. Müller-Schweinitzer
  • E. Schlicker
  • L. Sistonen
  • P. A. Stadler
Article

Summary

The affinities of 16 5-hydroxytryptamine (5-HT) receptor agonists (indole derivatives) and 7 5-HT receptor antagonists for [3H]5-hydroxytryptamine ([3H]5-HT) binding sites in rat cerebral cortex membranes were determined. In addition, the potencies of the agonists for inhibiting the electrically induced tritium overflow from rat brain cortex slices preincubated with [3H]5-HT and from canine saphenous veins preincubated with [3H]noradrenaline were measured. Furthermore, the potencies of the indole derivatives for inducing contractile responses of canine saphenous veins were recorded. In addition, the interaction of the antagonists with unlabelled 5-HT at the 5-HT autoreceptor was studied in rat brain cortex slices.

There was a good correlation between the binding affinities of the indole derivatives for the [3H]5-HT sites of rat brain cortex membranes and their potencies for inhibiting the evoked tritium overflow from both rat brain cortex slices and strips of canine saphenous vein. Comparison of the inhibition constants derived from the overflow experiments in both tissues again revealed a high correlation coefficient while there was only weak correlation between the binding affinities in rat brain cortex and the contractile potencies of the drugs in canine saphenous vein strips.

When 5-HT receptor antagonists were investigated, metitepin and metergoline showed moderate affinities for the 5-HT autoreceptors in rat brain cortex slices, whereas quipazine had only weak affinity, and ketanserin, metoclopramide, cinanserin and cyproheptadine exhibited no antagonistic property. In binding experiments, the competition curves of most 5-HT receptor antagonists were biphasic, suggesting that the [3H]5-HT binding sites are heterogeneous. The affinities of the antagonists to the low affinity binding sites were roughly in accordance with their affinities for the 5-HT autoreceptors determined in release experiments.

It is concluded that [3H]5-HT binding sites, presynaptic 5-HT autoreceptors in the rat brain cortex and inhibitory presynaptic 5-HT receptors on sympathetic nerve endings in the canine saphenous vein possess common pharmacological properties. In the rat brain cortex, the 5-HT1 sites are not homogeneous. Part of the [3H]5-HT binding sites (low affinity sites rather than high affinity sites) may be localized on the serotoninergic neurones and, hence, be identical with the serotonin autoreceptors. The results are also compatible with the suggestion that there may exist even more than two subtypes of [3H]5-HT1 binding sites in the rat brain cortex.

Key words

[3H]5-HT binding sites 5-HT autoreceptors Presynaptic receptors Rat cerebral cortex Canine saphenous vein 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Apperley E, Feniuk W, Humphrey PPA, Levy GP (1980) Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br J Pharmacol 68:215–224Google Scholar
  2. Baumann PA, Waldmeier PC (1981) Further evidence for negative feedback control of serotonin release in the central nervous system. Naunyn-Schmiedeberg's Arch Pharmacol 317:36–43Google Scholar
  3. Engel G, Hoyer D, Berthold R, Wagner H (1981) (±) [125Iodo]-cyanopindolol, a new ligand for β-adrenoceptors: Identification and quantitation of subclasses of β-adrenoceptors in guinea pig. Naunyn-Schmiedeberg's Arch Pharmacol 317:277–285Google Scholar
  4. Engel G, Müller-Schweinitzer E, Stadler PA (1983) [125I]LSD, a new ligand with selectivity for 5-HT2 receptors. Br J Pharmacol 78:83PGoogle Scholar
  5. Feniuk W, Humphrey PPA, Watts AD (1979) Presynaptic inhibitory action of 5-hydroxy-tryptamine in dog isolated saphenous vein. Br J Pharmacol 67:247–254Google Scholar
  6. Fozard JR (1983) Functional correlates of 5-HT1 recognition sites. Trends Pharmacol Sci (in press)Google Scholar
  7. Fozard JR, Mwaluko GMP (1976) Mechanism of the indirect sympathomimetic effect of 5-hydroxytryptamine on the isolated heart of the rabbit. Br J Pharmacol 57:115–125Google Scholar
  8. Fozard JR, Mobarok Ali ATM (1978a) Receptors for 5-hydroxytryptamine on the sympathetic nerves of the rabbit heart. Naunyn-Schmiedeberg's Arch Pharmacol 301:223–235Google Scholar
  9. Fozard JR, Mobarok Ali ATM (1978b) Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 49:109–112Google Scholar
  10. Furchgott RF (1972) The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E (eds) Handbook of experimental pharmacology. Catecholamines, vol XXXIII. Springer, Berlin Heidelber New York, pp 283–335Google Scholar
  11. Gaddum JH, Picarelli ZP (1957) Two kinds of tryptamine receptors. Br J Pharmacol 12:323–328Google Scholar
  12. Göthert M (1980) Serotonin-receptor-mediated modulation of Ca2+-dependent 5-hydroxytryptamine release from neurones of the rat brain cortex. Naunyn-Schmiedeberg's Arch Pharmacol 314:223–230Google Scholar
  13. Göthert M (1982) Modulation of serotonin release in the brain via presynaptic receptors. Trends Pharmacol Sci 3:437–440Google Scholar
  14. Göthert M, Dührsen U (1979) Effects of 5-hydroxytryptamine and related compounds on the sympathetic nerves of the rabbit heart. Naunyn-Schmiedeberg's Arch Pharmacol 308:9–18Google Scholar
  15. Göthert M, Schlicker E (1983) Autoreceptor-mediated inhibition of 3H-5-hydroxytryptamine release from rat brain cortex slices by analogues of 5-hydroxytryptamine. Life Sci 32:1183–1191Google Scholar
  16. Göthert M, Weinheimer G (1979) Extracellular 5-hydroxytryptamine inhibits 5-hydroxytryptamine release from rat brain cortex slices. Naunyn-Schmiedeberg's Arch Pharmacol 310:93–96Google Scholar
  17. Göthert M, Schlicker E, Kösterman F (1983) Relationship between transmitter uptake inhibition and effects of α-adrenoceptor agonists on serotonin and noradrenaline release in the rat brain cortex. Naunyn-Schmiedeberg's Arch Pharmacol 322:121–128Google Scholar
  18. Hamon M, Nelson DL, Mallat M, Bourgoin S (1981) Are 5-HT receptors involved in the sprouting of serotonergic terminals following neonatal 5,7-dihydroxytryptamine treatment in the rat? Neurochem Int 3:69–79Google Scholar
  19. Leysen JE (1981) Serotoninergic receptors in brain tissue: Properties and identification of various 3H-ligand binding sites in vitro. J Physiol (Paris) 77:351–362Google Scholar
  20. Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) [3H]-Ketanserin (R41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21:301–314Google Scholar
  21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275Google Scholar
  22. Mullat M, Hamon M (1982) Calcium guanine nucleotide interactions in brain membranes. I. Modulation of central 5-HT receptors in the rat. J Neurochem 38:151–161Google Scholar
  23. Martin LL, Sanders-Bush E (1982a) Comparison of the pharmacological characteristics of 5-HT1 and 5-HT2 binding sites with those of serotonin autoreceptors which modulate serotonin release. Naunyn-Schmiedeberg's Arch Pharmacol 321:165–170Google Scholar
  24. Martin LL, Sanders-Bush E (1982b) The serotonin autoreceptor: Antagonism by quipazine. Neuropharmacology 21:445–450Google Scholar
  25. McGrath MA (1977) 5-Hydroxytryptamine and neurotransmitter release in canine blood vessels. Inhibition by low and augmentation by high concentrations. Circ Res 41:428–435Google Scholar
  26. McGrath MA, Shepherd JT (1976) Inhibition of adrenergic neurotransmission in vascular smooth muscle by 5-hydroxytryptamine. Circulation (Suppl) 54 11–20:0071Google Scholar
  27. Müller-Schweinitzer E (1981) Agonist potencies of tryptamine derivatives at pre- and postjunctional receptors in canine saphenous vein. Postgrad Med J (Suppl) 57:36–44Google Scholar
  28. Müller-Schweinitzer E (1982) Actions of Co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn-Schmiedeberg's Arch Pharmacol 318:225–233Google Scholar
  29. Nahorski SR, Willcocks AL (1983) Interaction of β-adrenoceptor antagonists with 5-hydroxytryptamine receptor subtypes in rat cerebral cortex. Br J Pharmacol 78:107PGoogle Scholar
  30. Nelson DL, Herbert A, Bourgoin S, Glowinski J, Hamon M (1978) Characteristics of central 5-HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat. Mol Pharmacol 14:983–995Google Scholar
  31. Nelson DL, Pedigo NW, Yamamura HI (1980) Multiple 3H-5-hydroxytryptamine binding sites in rat brain. J Physiol (Paris) 77:369–372Google Scholar
  32. Nelson DL, Schnellmann R, Smit M (1983) 3H-Serotonin binding sites: Pharmacological and species differences. In: Segawa T, Yamamura HI, Kuriyama K (eds) Molecular pharmacology of neurotransmitter receptors. Raven Press, New YorkGoogle Scholar
  33. Ortmann R, Bischoff S, Radeke E, Buech O, Delini-Stula A (1982) Correlations between different measures of antiserotonin activity of drugs. Study with neuroleptics and serotonin receptor blockers. Naunyn-Schmiedeberg's Arch Pharmacol 321:265–270Google Scholar
  34. Pedigo NW, Yamamura HJ, Nelson DL (1981) Discrimination of multiple [3H]5-hydroxytryptamine binding sites by neuroleptic spiperone in rat brain. J Neurochem 36:220–226Google Scholar
  35. Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: Differential binding of [3H]5-hydroxytryptamine, [3H]-lysergic acid diethylamide and [3H]-spiroperidol. Mol Pharmacol 16:687–699Google Scholar
  36. Peroutka SJ, Snyder SH (1982) In: Osborne NN (ed) Biology of serotonergic transmission. John Wiley and Sons, New York, pp 279–295Google Scholar
  37. Peroutka SJ, Lebovitz RM, Snyder SH (1979) Serotonin receptor binding sites affected differentially by guanine nucleotides. Mol Pharmacol 16:700–708Google Scholar
  38. Peroutka SJ, Lebovitz RM, Snyder SH (1981) Two distinct central serotonin receptors with different physiological functions. Science 212:827–829Google Scholar
  39. Petersen EN, Olsson SO, Squires RF (1977) Effects of 5-HT uptake inhibitors on the pressor response to 5-HT in the pithed rat. The significance of the 5-HT blocking property. Eur J Pharmacol 43:209–215Google Scholar
  40. Rorie DK, Muldoon SM, Tyce GM (1980) The specific activity of retained and released norepinephrine in dog saphenous vein prelabeld with radiolabeled norepinephrine. Life Sci 26:707–714Google Scholar
  41. Schlicker E, Göthert M (1981) Antagonistic properties of quipazine at presynaptic serotonin receptors and α-adrenoceptors in rat brain cortex slices. Naunyn-Schmiedeberg's Arch Pharmacol 317:204–208Google Scholar
  42. Snedecor GW, Cochran WG (1973) Curvilinear regression. In: Snedecor GW, Cochran WG (eds) Statistical methods, chapter 15. The Iowa State Univ Press, Iowa, 6th edtn, pp 447–471Google Scholar
  43. Snyder SH, Peroutka SJ (1981) Multiple neurotransmitter receptors: Two populations of serotonin receptors with different physiological functions. In: Yamamura HI, Olsen R, Usdin E (eds) Psychopharmacology and biochemistry of neurotransmitter receptors. Elsevier North Holland Inc, Amsterdam, pp 318–324Google Scholar
  44. Vaatstra WJ, Deiman-Van Aalst WMA, Eigeman L (1981) DU 24565, a quipazine derivative, a potent selective serotonin uptake inhibitor. Eur J Pharmacol 70:195–202Google Scholar
  45. Van Nueten JM, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren TH, Vanhoutte PM (1981) Vascular effects of ketanserin (R41 468), a novel antagonist of 5-HT2 serotoninergic receptors. J Pharmacol Exp Ther 218:217–230Google Scholar
  46. Van Rossum JM (1963) Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn 143:299–330Google Scholar
  47. Watts AD, Feniuk W, Humphrey PPA (1981) A pre-junctional action of 5-hydroxytryptamine and methysergide on noradrenergic nerves in dog isolated saphenous vein. J Pharm Pharmacol 33:515–520Google Scholar
  48. Whitaker PM, Deakin JFW (1981) Does [3H]serotonin label presynaptic receptors in rat frontal cortex? Eur J Pharmacol 73:349–351Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • G. Engel
    • 1
  • M. Göthert
    • 2
  • E. Müller-Schweinitzer
    • 1
  • E. Schlicker
    • 2
  • L. Sistonen
    • 1
  • P. A. Stadler
    • 1
  1. 1.Preclinical ResearchSandoz Ltd.BaselSwitzerland
  2. 2.Pharmakologisches Institut der Universität EssenEssen 1Federal Republic of Germany

Personalised recommendations